Get the latest news alerts: at Twitter.


NEW YORK — Shares in GlaxoSmithKline (NYSE: GSK) fell 2.5 percent, or 94 cents, percent Monday following a critical report about the company and its diabetes drug Avandia.

GSK closed at $37.32..

However, the U.S. Food and Drug Administration issued a "safety announcement" in which it urged Avandia patients to not stop taking the drug until they had talked with a health care professional.


Also on Monday, GSK Chief Executive Officer Andrew Witty said the company would build a new biotechnology plant in the U.K. Witty made the announcement at an investors conference, Dow Jones news service reported. Witty cited new legislation that lowered taxes on patents as a reason for picking the U.K. for the plant that will employ 1,000 people.

"As a direct result of the commitment from the government to create a patent box, we will build our next major greenfield manufacturing center, biopharmaceutical factory, here in Britain," he said, according to Dow Jones.

A Senate report said Saturday that knew of possible heart attack risks tied to Avandia, its diabetes medication, years before such evidence became public.

GSK issued a statement rebutting the report’s conclusions. ()

However, just how bad the news will be for GSK from a financial standpoint remains to be seen.

"Whether or not the ultimate decision is to remove Avandia from the U.S. market remains to be seen, but ultimately the impact on GSK would be limited given that our forecasts suggest that U.S. Avandia sales comprise only circa 1.5 percent of the company’s sales now," Shore Capital analyst Brian White told Reuters news service.

Sen. Max Baucus, chairman of the Senate Finance Committee, and Chuck Grassley, the committee’s ranking Republican, released the report, which follows a two-year inquiry, on Saturday.

They are also asking the why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007.

The agency ordered a warning to be included on Avandia’s label in 2007, saying that it might increase the risk of heart attacks, though the data on those risk was inconclusive.

Soon afterwards Sen. Grassley, one of the FDA’s toughest critics in Congress, disclosed that the agency’s internal safety experts came within one vote of recommending a withdrawal of Avandia.


The Senate report suggests sharp disagreements remain at the FDA over how to handle Avandia’s risks.

In a letter to FDA Commissioner Margaret Hamburg that was also released Saturday, the senators said the committee’s report was based on researchers’ studies of Avandia, internal GlaxoSmithKline documents and FDA documents. They said committee investigators had interviewed GlaxoSmithKline and agency employees as well as what it called anonymous whistleblowers.

Based on its knowledge of the heart attack risks, GlaxoSmithKline “had a duty to sufficiently warn patients and the FDA of its concerns in a timely manner,” the report said.

Instead, the company tried to downplay findings that the drug could increase cardiovascular risks while also working to downplay findings that a rival medication might reduce such risks, it said.

GlaxoSmithKline, which maintains its U.S. headquarters in Research Triangle Park, N.C., said in a statement the drug is safe. It said the committee report took data out of context from analyses of Avandia.


In May 2007, the New England Journal of Medicine published an analysis of dozens of studies on nearly 28,000 people who had taken Avandia. The journal said there was a 43 percent higher risk of heart attack for those taking Avandia compared to people taking other diabetes drugs or no diabetes medication. The findings raised concerns because two-thirds of the people with Type 2 diabetes, the most common form, die of heart problems.

“Contrary to the assertions in the report, and consistent with the FDA-approved labeling, the scientific evidence simply does not establish that Avandia increases cardiovascular ischemic risk or causes myocardial ischemic events,” GlaxoSmithKline said.

"Contrary to the assertions in the report, and consistent with the FDA-approved labelling, the scientific evidence simply does not establish that Avandia increases cardiovascular ischemic risk or causes myocardial ischemic events," the statement added.

"In 2007, the FDA considered all the available scientific evidence on Avandia, including Dr. David Graham’s assertions of elevated heart attack risk and demands that the product be withdrawn. Based on the scientific evidence and a recommendation by an independent advisory committee of experts convened by the FDA, the agency has ruled that Avandia remain available to patients for the treatment of Type 2 diabetes."

In their letter to Hamburg, the senators said the documents the committee reviewed included an analysis conducted by two safety officials at the agency. The analysis compared Avandia to Takeda Pharmaceutical’s diabetes drug Actos, and found that Avandia has an increased risk of heart attack and heart failure. Actos is co-promoted by Pfizer Inc.

At FDA’s request, Glaxo agreed in 2007 to conduct a six-year study between its drug and Actos, to give a definitive picture of Avandia’s safety. The study, which will involve 16,000 participants, is still enrolling patients.

But FDA researchers quoted in the report called the study “unethical and exploitative,” since patients will continue taking Avandia, a drug with known risks, over Actos, which has not shown any links to heart prblems.

FDA spokesman George Strait said the FDA is reviewing new data on Avandia and will present those findings to an advisory committee this summer.

“Meanwhile, Commissioner Hamburg is reaching out to ensure that she has a complete understanding and awareness of all of the data and issues concerning this drug,” Strait said.

Avandia was Glaxo’s third best-selling drug in 2006 with revenue of $2.2 billion. But the safety concerns disclosed the following year slashed revenue to $1.2 billion by the end of 2008.

Avandia is intended to control blood sugar by increasing the body’s sensitivity to insulin, a protein critical to digesting sugars.

Insulin-regulating treatments have long been presumed to lessen the heart risks already associated with diabetes, which is linked to obesity.